Clinical Trial Update: Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating atropine to prevent dysrhythmias caused by percutaneous ethanol instillation during hepatocellular carcinoma therapy has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atropine (atropine)

Snippet

Sponsor: Medical University of Vienna | Conditions: Arrhythmia, Respiratory Arrest | Phase 4 | Status: COMPLETED